Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Aug 6, 2021
- Accession no.
- 0001447362-21-000184
- Filed
- Aug 6, 2021
- Trade date
- Aug 3, 2021
- Filing delay
- 3 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $282.8K. It was filed 3 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 3, 2021 | Common Stock | SSaleDisposed | −1,340 | $70.35F2 | −$94,269 | 151,461 | Indirect | |
| Aug 3, 2021 | Common Stock | SSaleDisposed | −1,340 | $70.35F2 | −$94,269 | 174,300 | Indirect | |
| Aug 3, 2021 | Common Stock | SSaleDisposed | −1,340 | $70.35F2 | −$94,269 | 161,699 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
These transactions were executed in multiple trades at prices ranging from $70.08 to $70.52, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 3 transactions in Table I.